

May 2, 2007



## Completion of Ballistic Testing

TORONTO, May 2 /PRNewswire-FirstCall/ -- Security Devices International, Inc. (OTC Bulletin Board: SDEV) -- a defense technology company specializing in the creation of non lethal ammunition solutions -- announced today that during the first quarter of 2007 the Company briefed the US Army RDECOM-ARDEC in Picatinny, New Jersey about its new Lektrox ammunition.

The team presented the patent-pending Lektrox as a solution compliant with Department of Defense specifications for both accuracy and non-lethality -- the latter is judged according to a projectile's penetration into a simulated human body.

Designed for accuracy up to a range of 60 yards, Lektrox is a unique 3rd generation solution that is being developed to instantly incapacitate targets. It does so without causing serious injury or lethality from either the built- in Wireless Electro-Muscular Disruption Technology (W-EMDT) or from the impact of the projectiles kinetic energy.

The team reported that both the 37/38mm and 40mm versions of its ammunition -- designed for use with standard riot guns and M203 grenade launchers -- were found to comply with the DoD requirements.

"We are pleased with the results of the latest briefing. As far as we are aware, Lektrox is the only projectile of its kind that complies with both these parameters," says SDI's CEO Sheldon Kales. "The conclusions confirm the success of our latest development period that resolved the final details of design -- the ballistics and aerodynamic stability needed to ensure the bullet's accurate delivery, and the mechanisms that guarantee non-injurious impact."

Mr. Kales went on to describe the unique triple mechanism that the Lektrox employs to reduce the projectile's kinetic energy levels. First is the use of a collapsible head whose materials enlarge the contact surface to absorb part of the impact. Further potentially dangerous energy is transferred to other mechanisms -- one that releases a Multiple Mini-Harpoon to affix the bullet to the target, the second that activates the bullet's built-in electrical system.

With clinical tests expected to be performed next month, SDI is now moving towards a full production file and preparations for the production of both the 37/38mm and 40mm versions of the Lektrox.

### Appointment of CFO

At the same time, the company announced the addition of Mr. Rakesh Malhotra as SDI's new CFO. Rakesh Malhotra has been SDI's Chief Financial Officer since January 7, 2007.

A United States Certified Public Accountant (CPA) and a Canadian Chartered Accountant, Mr. Malhotra graduated with Bachelor of Commerce (Honors) from the University Delhi, India, and worked for A.F Ferguson & Co. (the Indian correspondent of KPMG).

Having practiced as a Chartered Accountant for over ten years in New Delhi, Mr. Malhotra moved to the Middle East and worked for five years with the International Bahwan Group in a senior finance position. Between 2000 and 2001 he worked as a Chartered Accountant with a medium sized accounting firm in Toronto and then worked for five years as the Vice President of Finance for a private group of companies in Toronto. Since 2005, Mr. Malhotra served as CFO of Yukon Gold Corporation Inc. and a consultant to a number of public companies.

#### More about SDI

The Company specializes in the field of non lethal technologies for defense industries. The company's R&D is being conducted in Israel by Elad Engineering Ltd. Elad's founders, Haim Danon and Ilan Shalev, previously held positions at Israeli Aircraft Industries (IAI) and Israeli Military Industries (IMI) leading such development projects as the Negev machine gun -- currently deployed by the IDF -- and the legendary Desert Eagle pistol, as well as other weapon systems.

SDI and Elad are supported by an internationally renowned team of specialists that includes Emmanuel Mendes, an electrical engineer with four decades experience at the forefront of development in Israel's leading technology industries; and Dr. Yoav Paz, a leading heart and chest surgeon from the Hadassah Medical Center Jerusalem and member of the European Cardiology Society.

Security Devices has not authorized the release of this press release in any form that contravenes any law or regulation and will not be responsible for the unsolicited distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward looking statements" within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. Security Devices intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, actual results could differ materially from expected results.

For more information about the Company visit: [www.lektrox.com](http://www.lektrox.com)

Contact [info@lektrox.com](mailto:info@lektrox.com) or phone Toll Free: 1877-LEKTROX 535-8769

SOURCE Security Devices International, Inc.